Spravato® (esketamine)

We offer Spravato®, a new and highly effective treatment for depression at our Hartford and Waterbury locations. Our patients are treated in a specially designed suite devoted specifically for patients receiving this treatment.

Spravato® (esketamine) is the first prescription nasal spray, taken with an oral antidepressant, which is FDA-approved for:

• Adults with treatment-resistant depression. Treatment-resistant depression (TRD) presents as depression in patients struggling with major depressive disorder who have not responded adequately to two or more antidepressants.
• Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts.

On treatment days, patients administer Spravato® nasal spray under the guidance and supervision of a physician at our Family Health & Wellness Center.

After administering Spravato®, there is an observation period of approximately two hours, during which patients relax and rest in the privacy of individual treatment rooms, while being monitored for rare, potential side effects. 

Due to the rare, though potential, side effects that may occur, primarily drowsiness or a mild elevation in blood pressure in the early part of treatment, patients receiving Spravato® therapy will utilize Veyo, Uber Health, or other transportation after each treatment, not drive themselves. Transportation is provided to all patients.

Side effects may last up to 24 hours, resolving completely with restful sleep. Most patients experience little or no fatigue.